Affinage

PBRM1

Protein polybromo-1 · UniProt Q86U86

Length
1689 aa
Mass
192.9 kDa
Annotated
2026-06-10
100 papers in source corpus 28 papers cited in narrative 28 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PBRM1/BAF180 is the chromatin-targeting subunit of the PBAF SWI/SNF chromatin-remodeling complex, controlling transcriptional programs that govern cell-cycle arrest, cellular differentiation, genome stability, and immune recognition (PMID:15601824, PMID:18339845, PMID:34551289). It tethers PBAF to chromatin through cooperative bromodomain recognition of acetylated histones: full-length PBRM1 binds H3K14ac via the collaborative action of bromodomains BD2, BD4 and BD5, and tumor-derived bromodomain mutations weaken this interaction, mislocalize PBRM1, and abolish its tumor-suppressor activity (PMID:29986887, PMID:30585695). The same bromodomains read additional acetyl marks and nucleic acids—BD4 recognizes p53 acetylated at K382 to promote p53 binding at target promoters including CDKN1A/p21, and BD2/BD4 also bind double-stranded RNA elements required for chromatin engagement (PMID:31863007, PMID:36808431). Through these targeting activities PBRM1 binds the p21 promoter to enforce p21-dependent G1 arrest and senescence, supports centromeric cohesion, and restrains replication stress and R-loop accumulation (PMID:18339845, PMID:24613357, PMID:26992241, PMID:33888468). In clear cell renal carcinoma, combined PBRM1 and VHL loss amplifies HIF and STAT3 transcriptional output, relieves VHL-induced replication stress, and drives tumorigenesis with convergence on mTORC1 (PMID:28329682, PMID:28082722, PMID:29229903, PMID:28473526). PBRM1 loss also causes ectopic PBAF redistribution to NF-κB enhancers and reduces BRG1 occupancy at the IFNγ receptor promoter, shaping a less immunogenic tumor microenvironment (PMID:37095322, PMID:32358509). Beyond its remodeling role, PBRM1 has a SWI/SNF-independent function cooperating with the m6A reader YTHDF2 to control HIF-1α mRNA translation, and its protein stability is governed by p53-induced, UBE3A-mediated proteasomal degradation (PMID:34200988, PMID:26178300, PMID:35368029).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2004 High

    Established PBRM1 as the defining PBAF-specific subunit and a chromatin-recruited transcriptional coactivator, framing all later mechanistic work.

    Evidence Mouse knockout, in vitro nuclear-receptor transcription assay, and ChIP at target promoters

    PMID:15601824

    Open questions at the time
    • Molecular basis of promoter targeting not defined
    • Did not address tumor-suppressor function
  2. 2008 High

    Showed PBRM1 controls developmental cell behaviors and links it to p21-dependent cell-cycle arrest, revealing both differentiation and growth-control roles.

    Evidence Knockout mouse epicardial EMT/migration assays and ChIP-coupled p21 induction in complemented tumor cells

    PMID:18339845 PMID:18508041

    Open questions at the time
    • Mechanism by which PBRM1 represses vs. activates p21 across contexts unresolved
    • Direct chromatin-reading determinants not yet mapped
  3. 2010 Medium

    Connected PBRM1 to p53-dependent senescence, positioning it within stress-response transcriptional control.

    Evidence Loss-of-function screen in primary human cells with p53 transcriptional readouts

    PMID:20660729

    Open questions at the time
    • Which p53 targets are PBRM1-dependent not fully defined
    • Single-lab functional screen
  4. 2012 High

    Identified non-transcriptional and lineage-specific roles—centromeric cohesion/genome stability and direct repression of the IL-10 locus in Th2 cells, with subunit competition by BAF250.

    Evidence Cohesion and chromosome-instability assays with tumor-mutant testing; ChIP and histone-acetylation/CBP analysis in KO T cells

    PMID:22336179 PMID:24613357

    Open questions at the time
    • Mechanism linking PBRM1 to cohesin loading unknown
    • Generality of BAF/PBAF subunit swapping across loci untested
  5. 2016 High

    Reinforced the p21 axis using conditional knockout and genetic epistasis, showing PBRM1 loss causes premature senescence rescuable by p21 deletion.

    Evidence Conditional mouse KO, ChIP, histone-modification analysis, and p21 genetic rescue

    PMID:26992241

    Open questions at the time
    • How PBRM1 toggles between p21 repression and induction unresolved
  6. 2017 High

    Defined PBRM1 as a renal tumor suppressor whose loss with VHL drives ccRCC by amplifying HIF/STAT3 output, relieving replication stress, and converging on mTORC1, and showed growth suppression requires intact PBAF assembly.

    Evidence Kidney-specific Vhl/Pbrm1 conditional KO mice, biochemical PBAF assembly assays, replication-stress markers, and mTORC1/Tsc1 epistasis

    PMID:28082722 PMID:28329682 PMID:28473526 PMID:29229903

    Open questions at the time
    • Direct chromatin targets mediating HIF amplification not enumerated
    • Mechanism of replication-stress rescue at the molecular level incomplete
  7. 2017 Medium

    Extended PBRM1 function to innate immune homeostasis and BAH-domain-dependent PCNA ubiquitination, showing complex- and domain-specific activities.

    Evidence Drosophila IMD-pathway epistasis with mouse infection model; BAF180 deletion-mutant PCNA-ubiquitination assays after UV

    PMID:26117423 PMID:28418397

    Open questions at the time
    • BAH-domain mechanism of promoting PCNA ubiquitination undefined
    • Single-lab domain-deletion analyses
  8. 2019 High

    Resolved the molecular logic of PBRM1 chromatin targeting: multivalent bromodomain reading of H3K14ac and p53-K382Ac, with tumor mutations disrupting binding and tumor suppression.

    Evidence Purified bromodomain and full-length binding assays, histone microarrays, BD mutagenesis, ChIP, transcriptional profiling, and xenografts

    PMID:29986887 PMID:30585695 PMID:31863007

    Open questions at the time
    • Structural basis of inter-bromodomain cooperativity not solved
    • Full acetyl-mark repertoire incompletely mapped
  9. 2020 Medium

    Linked PBRM1 to tumor immune recognition through both IFNγ/STAT1 signaling and NK-cell-mediated killing, establishing an immunological dimension to its loss.

    Evidence ChIP of BRG1 at Ifngr2, STAT1 phosphorylation assays, and genome-wide CRISPR NK-killing screens with ligand/granule readouts

    PMID:32358509 PMID:33246952

    Open questions at the time
    • Causal chain from chromatin to NK ligand expression incomplete
    • Single-study findings for each axis
  10. 2021 High

    Defined PBRM1 as a guardian against replication stress/R-loops and a context-specific PAX8 coactivator, while revealing a SWI/SNF-independent translational role via YTHDF2.

    Evidence Functional genomic screens with RNase H1 rescue and synthetic-lethality assays; PAX8 interactome proteomics with reciprocal Co-IP and ChIP; PBRM1-YTHDF2 Co-IP/RNA-IP and translation assays

    PMID:33888468 PMID:34200988 PMID:34551289

    Open questions at the time
    • Which R-loop processing factors are direct PBRM1 transcriptional targets unclear
    • YTHDF2 cooperation rests on single-lab Co-IP/RNA-IP
  11. 2022 High

    Showed PBRM1 loss produces gain-of-function via ectopic PBAF redistribution to NF-κB enhancers and defined how PBRM1 protein levels are controlled by p53-induced UBE3A-mediated degradation.

    Evidence ChIP-seq of PBAF subunit redistribution with SMARCA4 ATPase mutants and bortezomib xenografts; pulse-chase, proteasome-inhibitor rescue, and PBRM1-UBE3A interactome/ubiquitination assays

    PMID:26178300 PMID:35013001 PMID:35368029 PMID:37095322

    Open questions at the time
    • Determinants directing ectopic PBAF to NF-κB motifs unresolved
    • Upstream signals coupling p53 to UBE3A-PBRM1 turnover incompletely defined
  12. 2023 Medium

    Broadened PBRM1's binding repertoire to double-stranded RNA and identified a MUC1-C partnership driving IFN-pathway transcription in breast cancer, indicating roles beyond renal cancer.

    Evidence In vitro RNA-binding and binding-pocket mutagenesis with chromatin/growth readouts; MUC1-C/PBRM1 Co-IP with RNA-seq and ATAC-seq

    PMID:36445328 PMID:36808431

    Open questions at the time
    • Functional role of RNA binding in chromatin targeting vs. other processes unclear
    • MUC1-C cooperation from a single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PBRM1's distinct activities—bromodomain acetyl/RNA reading, PBAF tethering, SWI/SNF-independent translation, and protein turnover—are integrated to specify locus selection and context-dependent tumor suppression versus gain-of-function remains unresolved.
  • No structural model of full-length PBRM1 engaging the nucleosome
  • Mechanism directing ectopic PBAF to oncogenic enhancers unknown
  • Integration of chromatin and RNA/translational functions undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003723 RNA binding 2 GO:0042393 histone binding 2 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 3 GO:0005654 nucleoplasm 2
Pathway
R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-4839726 Chromatin organization 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1640170 Cell Cycle 2 R-HSA-73894 DNA Repair 2
Partners
ARID2BRD7MUC1PAX8SMARCA4TP53UBE3AYTHDF2
Complex memberships
PBAF SWI/SNF complex

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 BAF180 (PBRM1) is a PBAF-specific subunit required for PBAF-mediated potentiation of nuclear receptor (RXRalpha, VDR, PPARgamma) transcriptional activation in vitro; ablation in mouse embryos causes hypoplastic ventricle development and trophoblast defects. BAF180 is recruited to promoters of target genes (S100A13, RARbeta2, CRABPII) and is required for retinoic acid response. Mouse knockout (BAF180 ablation), embryonic aggregation analysis, in vitro transcriptional activation assay, chromatin immunoprecipitation (ChIP) Genes & development High 15601824
2008 BAF180 (PBRM1) is required for epicardial epithelial-to-mesenchymal transition (EMT) and coronary vessel development; BAF180 mutant epicardial cells show compromised migration and EMT potentials, and expression of FGF, TGF, and VEGF pathway genes is downregulated in mutant hearts. BAF180 knockout mouse model, 3D collagen gel migration/EMT assay, PECAM and alpha-SMA staining, quantitative RT-PCR Developmental biology High 18508041
2008 BAF180 (PBRM1) is required for proper p21/WAF1/CIP1 expression and G1 arrest; endogenous BAF180 binds to the p21 promoter and is required for p21 induction by TGF-beta and gamma-radiation. BAF180 complementation of BAF180-mutant tumor cells causes G1 arrest dependent on p21 upregulation. Cell complementation of BAF180-mutant tumor cells, chromatin immunoprecipitation (ChIP) at p21 promoter, TGF-beta/gamma-radiation treatment, cell cycle analysis Cancer research High 18339845
2010 BAF180 (PBRM1) regulates p53 transcriptional activity toward a subset of p53 target genes required for replicative and oncogenic stress senescence induction. Loss of BAF180 impairs replicative senescence in primary human cells. Loss-of-function genetic screen in primary human cells, p53 transcriptional activity assays Proceedings of the National Academy of Sciences of the United States of America Medium 20660729
2012 BAF180 (PBRM1) is required for centromeric cohesion in mouse and human cells. Cancer-associated BAF180 mutations fail to support cohesion, and BAF180 loss leads to dynamic chromosome instability following DNA damage. BAF180 depletion in mouse and human cells, cohesion assay, chromosome instability analysis, functional testing of tumor-derived mutants in yeast cohesion assay Cell reports High 24613357
2012 BAF180 (PBRM1) directly binds regulatory elements in the IL-10 locus and represses IL-10 transcription in Th2 cells. In the absence of BAF180, BAF250-containing BAF complexes replace it at the IL-10 locus, resulting in increased histone acetylation and CBP recruitment. BAF180-deficient mouse T cells, ChIP at IL-10 locus, histone acetylation assay, CBP recruitment analysis BMC immunology High 22336179
2015 BAH domains of BAF180 (PBRM1) are required for PCNA ubiquitination during S-phase after UV irradiation; the BAH domain region promotes PCNA ubiquitination independent of PBAF complex assembly and ATPase activity. Expression of BAF180 deletion mutants in cells, ubiquitinated PCNA western blot, UV irradiation assay, PBAF assembly analysis Mutation research Medium 26117423
2016 BAF180 (PBRM1) deletion in primary mouse embryonic fibroblasts triggers cell cycle arrest and premature cellular senescence through elevated p21 expression. BAF180 binds the p21 promoter and suppresses its transcription; BAF180 deletion enhances binding of activation-associated histone modifications to the p21 promoter. Deletion of p21 rescues senescence in BAF180-deficient MEFs. Conditional somatic knockout in mice, ChIP at p21 promoter, histone modification analysis, p21 genetic rescue experiment, hematopoietic stem cell functional assays Oncotarget High 26992241
2017 PBRM1 loss amplifies HIF1 and STAT3 transcriptional outputs driven by VHL deficiency. Combined kidney-specific deletion of Vhl and Pbrm1 (but not either alone) results in multifocal, transplantable clear cell kidney cancers in mice, with convergence on mTOR activation as a third driver event. Kidney-specific conditional knockout of Vhl and Pbrm1 in mice, transcriptional analysis, mTOR pathway analysis, tumor transplantation assay Cell reports High 28329682
2017 PBRM1 inactivation amplifies the HIF transcriptional signature in VHL-null ccRCC. BAF180 growth suppression requires formation of a canonical PBAF complex containing BRG1; a tumor-associated BAF180 mutant fails to form this complex and does not suppress growth. ccRCC cell line proliferation assays in vitro and in vivo xenograft, biochemical PBAF complex assembly assay, HIF transcriptional signature analysis Proceedings of the National Academy of Sciences of the United States of America High 28082722
2017 Bap1 and Pbrm1 loss (with Vhl) in PAX8-expressing cells drives ccRCC of different grades in mice; Bap1-deficient tumors are high grade with greater mTORC1 activation than Pbrm1-deficient tumors. Disrupting one Tsc1 allele in Pbrm1-deficient kidneys triggers higher grade ccRCC, implicating mTORC1 as a grade rheostat. Conditional KO mouse models with multiple Cre drivers, histological grading, mTORC1 pathway analysis, genetic epistasis (Tsc1 heterozygous deletion) Cancer discovery High 28473526
2017 Loss of VHL alone causes DNA replication stress and damage accumulation that constrains cellular growth; concomitant PBRM1 loss rescues VHL-induced replication stress, maintaining cellular fitness and allowing proliferation. Combined Vhl/Pbrm1 deletion in mouse kidney is sufficient for fully-penetrant multifocal carcinomas. VHL/PBRM1 co-deletion in cells and conditional KO mouse, DNA replication stress assays (DNA damage markers), proliferation assays Nature communications High 29229903
2017 Drosophila Bap180 (ortholog of PBRM1/BAF180) is induced by IMD-Relish signaling in the gut and feeds back to restrain overreactive IMD signaling and repress TNF/eiger expression, maintaining intestinal innate immune homeostasis. Intestinal Baf180 targeting in mice increases susceptibility to Citrobacter rodentium infection. Drosophila intestinal Bap180 knockdown/overexpression, infection models, genetic epistasis with IMD pathway, mouse intestinal Baf180 targeting Nature microbiology Medium 28418397
2018 PBRM1 bromodomains BD2 and BD4 mediate binding to acetylated histone peptides and modified nucleosomes. BD1 and BD5 enhance nucleosome interactions of BD2 and BD4 respectively, while BD3 attenuates them. Binding-pocket missense mutations in BD4 (but not BD2) found in ccRCC disrupt PBRM1-chromatin interactions and accelerate ccRCC cell proliferation. Histone microarrays, nucleosome binding assays with recombinant and cellular nucleosomes, BD missense mutant analysis, ccRCC cell proliferation assay The Journal of biological chemistry High 29986887
2019 PBRM1 acts as a reader of p53 acetylation at lysine 382 (K382Ac) through its bromodomain 4 (BD4). Mutations on key BD4 residues disrupt recognition of p53 K382Ac, reduce p53 binding to target promoters (including CDKN1A/p21), impair p53 transcriptional activity, and abolish PBRM1 tumor suppressor function in kidney cancer xenografts. Biochemical binding assay (PBRM1 BD4 with K382Ac p53 peptide), ChIP at CDKN1A promoter, BD4 mutagenesis, p53 transcriptional reporter, xenograft tumor suppression assay Nature communications High 31863007
2019 Full-length PBRM1 (but not individual bromodomains) strongly binds H3K14ac; BDs 2, 4, and 5 collaborate for high-affinity H3K14ac binding. Simultaneous point mutations in BDs 2, 4, and 5 prevent H3K14ac recognition, alter promoter binding, change gene expression, and cause PBRM1 to relocalize to the cytoplasm. Tumor-derived BD2 mutations alone weaken H3K14ac binding and abolish tumor suppressor activity in xenografts. Purified BD protein binding assays (quantitative), full-length PBRM1 H3K14ac binding assay, BD mutagenesis, ChIP, transcriptional profiling, xenograft tumor suppression, subcellular localization by imaging Molecular oncology High 30585695
2020 PBRM1/Pbrm1 deficiency reduces binding of BRG1 to the IFNγ receptor 2 (Ifngr2) promoter, decreasing STAT1 phosphorylation and subsequent expression of IFNγ target genes, leading to a less immunogenic tumor microenvironment. ChIP (BRG1 at Ifngr2 promoter), STAT1 phosphorylation assay, PBRM1-deficient cell lines and murine models, patient cohort analysis Nature communications Medium 32358509
2020 BMPs and osteogenic signals in mesenchymal stromal cells selectively induce PBAF components Pbrm1, Arid2, and Brd7. Pbrm1/PBAF deficiency impairs Smad1/5/8 activation through locus-specific epigenomic remodeling involving Pbrm1 bromodomains, and transcriptionally downregulates Bmpr/TgfβrII expression. Gain of function of BmprIβ/TgfβrII in PBAF-deficient MSCs partly restores osteogenesis. Conditional Pbrm1 loss in MSCs, ATAC-seq/ChIP-seq (bromodomain-specific), Smad1/5/8 activation assay, BmprIβ/TgfβrII rescue experiment, in vivo ossification assay Cell reports Medium 32348751
2021 PBRM1 deficiency causes elevated replication stress, micronuclei, and R-loops in cells; multiple R-loop processing factors are downregulated in PBRM1-defective tumor cells. PARP and ATR inhibitors are synthetic lethal with PBRM1 deficiency, and exogenous RNase H1 expression reverses PARP inhibitor sensitivity in PBRM1-deficient cells, implicating R-loop accumulation as a mechanistic basis. Functional genomic screens, R-loop quantification, replication stress markers, quantitative mass spectrometry of R-loop factors, RNase H1 rescue experiment, xenograft model Cancer research High 33888468
2021 PAX8 (master proximal tubule transcription factor) recruits PBRM1/PBAF specifically (not BAF) as a coactivator. In RCC cells lacking PBRM1, corepressors dominate the PAX8 hub, repressing key PAX8 target genes with loss of H3K27 acetylation. Re-introduction of PBRM1, or depletion of opposing corepressors, restores PAX8 target gene expression and induces terminal epithelial differentiation. Unbiased proteomics (PAX8 interactome), reciprocal Co-IP (PAX8-PBRM1/PBAF), ChIP (H3K27ac, H3K4me3), PBRM1 re-expression, siRNA corepressor depletion, terminal differentiation assay Cell reports High 34551289
2021 PBRM1 cooperates with YTHDF2 (an m6A reader) to control HIF-1α protein translation; PBRM1 (but not BRG1) interacts with YTHDF2, and HIF-1α mRNA is m6A-modified and bound by both PBRM1 and YTHDF2. PBRM1 is required for YTHDF2 binding to HIF-1α mRNA. This represents a SWI/SNF-independent function for PBRM1. Co-IP (PBRM1-YTHDF2 interaction), RNA immunoprecipitation (HIF-1α mRNA), polysome/translation assay, PBRM1 KD with HIF-1α protein/mRNA analysis Cells Medium 34200988
2022 PBRM1 deficiency results in ectopic PBAF complexes that localize to de novo genomic loci (distal enhancers with NF-κB motifs), activating the pro-tumorigenic NF-κB pathway. PBRM1-deficient PBAF retains SMARCA4-ARID2 association but has loosely tethered BRD7. SMARCA4 ATPase activity maintains chromatin occupancy of RELA at newly acquired sites, and proteasome inhibitor bortezomib suppresses RELA occupancy and delays PBRM1-deficient tumor growth. ChIP-seq (PBAF subunit redistribution), Co-IP (PBAF complex composition), SMARCA4 ATPase mutant analysis, RELA ChIP, bortezomib treatment in vivo xenograft Nature cell biology High 37095322
2022 PBRM1 is degraded via proteasomal degradation induced by p53 activation. p53-dependent PBRM1 regulation is post-translational (not transcriptional), as demonstrated by pulse-chase experiments and proteasome inhibitor rescue. siRNA knockdown of p53, pulse-chase experiment, proteasome inhibitor treatment, RCC cell lines and ex vivo tissue The Journal of pathology Medium 26178300
2022 UBE3A (an E3 ubiquitin ligase) binds PBRM1 and regulates its stability via ubiquitin-mediated proteasomal degradation. RBPJ/DAPK3 modulates UBE3A E3 ligase activity by interfering with PKA phosphorylation of UBE3A. The RBPJ/DAPK3/UBE3A axis controls PBRM1 protein levels and downstream p21 expression, affecting RCC sensitivity to CDK4/6 inhibitors. Unbiased mass spectrometry of PBRM1 interactome, Co-IP (PBRM1-UBE3A), ubiquitination assay, PKA phosphorylation of UBE3A, PBRM1 stability assay, CDK4/6 inhibitor sensitivity assay Cell death & disease Medium 35368029
2022 PBRM1 inactivation upregulates human endogenous retroviruses (hERVs) in a HIF1α- and HIF2α-dependent manner in ccRCC, as confirmed by in vitro PBRM1, HIF1A, and HIF2A silencing followed by RNA sequencing. RNA sequencing after siRNA knockdown of PBRM1/HIF1A/HIF2A, TCGA and IMmotion150 cohort analysis Cancer immunology research Medium 35013001
2023 MUC1-C is necessary for PBRM1 expression and forms a nuclear complex with PBRM1 in triple-negative breast cancer cells. MUC1-C and PBRM1 cooperatively drive STAT1 and IRF1 expression by increasing chromatin accessibility at their gene promoters (shown by RNA-seq and ATAC-seq), promoting chronic IFN pathway activation and DNA damage resistance. Co-IP (MUC1-C/PBRM1 nuclear complex), RNA-seq, ATAC-seq, MUC1-C knockdown, PBRM1 dependency analysis, DNA damage assays Molecular cancer research : MCR Medium 36445328
2023 PBRM1 bromodomains BD2 and BD4 bind double-stranded RNA elements in addition to acetylated histones. Disruption of the RNA-binding pocket compromises PBRM1 chromatin binding and inhibits PBRM1-mediated cellular growth suppression effects. In vitro RNA binding assays (BD2, BD4), RNA-binding pocket mutagenesis, chromatin binding assay, cellular growth assay Nucleic acids research Medium 36808431
2020 PBRM1 loss in tumor cells causes resistance to MHC-unrestricted cytotoxic lymphocyte (NK cell) killing in genome-wide genetic screens. PBRM1 and the GPI biosynthetic pathway regulate NK cell receptor ligands on tumor cells and promote cytolytic granule secretion in cytotoxic lymphocytes. Genome-wide CRISPR/genetic screen, NK cell killing assay, NK cell receptor ligand expression analysis, cytolytic granule secretion assay Science advances Medium 33246952

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 1011 21248752
2013 Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. The Lancet. Oncology 377 23333114
2005 Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS pathogens 296 16201016
2014 Influenza A virus protein PB1-F2 translocates into mitochondria via Tom40 channels and impairs innate immunity. Nature communications 200 25140902
2017 The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell reports 170 28329682
2015 The PB1 domain in auxin response factor and Aux/IAA proteins: a versatile protein interaction module in the auxin response. The Plant cell 163 25604444
2020 Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy. Autophagy 162 32013669
2006 Cell signaling and function organized by PB1 domain interactions. Molecular cell 162 16949360
2017 Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer discovery 148 28473526
2020 PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature communications 147 32358509
2010 Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proceedings of the National Academy of Sciences of the United States of America 147 20660729
2004 Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. Genes & development 147 15601824
2001 Novel modular domain PB1 recognizes PC motif to mediate functional protein-protein interactions. The EMBO journal 141 11483497
2015 TRIM32 Senses and Restricts Influenza A Virus by Ubiquitination of PB1 Polymerase. PLoS pathogens 140 26057645
2008 BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer research 135 18339845
2007 Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants. Science's STKE : signal transduction knowledge environment 127 17726178
2017 Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 125 28082722
2021 The PB1 protein of influenza A virus inhibits the innate immune response by targeting MAVS for NBR1-mediated selective autophagic degradation. PLoS pathogens 122 33577621
2012 Loss of PBRM1 expression is associated with renal cell carcinoma progression. International journal of cancer 122 22949125
2015 Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. The Journal of urology 116 26300218
2013 Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes, chromosomes & cancer 113 24166983
2021 PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer research 101 33888468
2013 PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer journal (Sudbury, Mass.) 98 23867514
2006 Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. The Journal of biological chemistry 92 16861740
2015 BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert review of molecular diagnostics 90 26166446
2019 Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status. AJR. American journal of roentgenology 86 30601030
2014 BAF180 promotes cohesion and prevents genome instability and aneuploidy. Cell reports 86 24613357
2017 Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis. Nature communications 85 29229903
2010 Influenza A virus protein PB1-F2 exacerbates IFN-beta expression of human respiratory epithelial cells. Journal of immunology (Baltimore, Md. : 1950) 84 20844191
2016 PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. PloS one 81 27100670
2010 Current knowledge on PB1-F2 of influenza A viruses. Medical microbiology and immunology 75 20953627
2009 Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell death and differentiation 66 19713972
2019 PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature communications 65 31863007
2008 Coronary development is regulated by ATP-dependent SWI/SNF chromatin remodeling component BAF180. Developmental biology 65 18508041
2007 The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages. Virology journal 62 17224071
2013 Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncology research 61 24063284
2019 Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia (New York, N.Y.) 57 30660076
2006 Structural characterization and oligomerization of PB1-F2, a proapoptotic influenza A virus protein. The Journal of biological chemistry 57 17052982
2022 PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Nature reviews. Urology 56 36253570
2016 BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget 56 26992241
1996 Influenza virus PB1 protein is the minimal and essential subunit of RNA polymerase. Archives of virology 55 8645093
2017 Evolution and Virulence of Influenza A Virus Protein PB1-F2. International journal of molecular sciences 54 29286299
2015 Amyloid Assemblies of Influenza A Virus PB1-F2 Protein Damage Membrane and Induce Cytotoxicity. The Journal of biological chemistry 50 26601953
2016 Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Protein-Protein Interaction as a Target for Next-Generation Anti-influenza Therapeutics. Journal of medicinal chemistry 49 27046062
2013 Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics 45 23644518
2020 PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer. NPJ precision oncology 44 32195359
2017 Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. Histopathology 40 27864835
2014 Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urologic oncology 39 25465300
2020 PB1-F2 protein of highly pathogenic influenza A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation through inhibition of MAVS-NLRP3 interaction. Journal of leukocyte biology 38 32386456
2017 Bap180/Baf180 is required to maintain homeostasis of intestinal innate immune response in Drosophila and mice. Nature microbiology 37 28418397
2018 A PB1-K577E Mutation in H9N2 Influenza Virus Increases Polymerase Activity and Pathogenicity in Mice. Viruses 36 30463209
2015 A germline mutation in PBRM1 predisposes to renal cell carcinoma. Journal of medical genetics 36 25911086
2020 Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-β Signaling. Cell reports 35 32348751
2003 The PB1 domain and the PC motif-containing region are structurally similar protein binding modules. The EMBO journal 35 14517229
2018 PBRM1 bromodomains variably influence nucleosome interactions and cellular function. The Journal of biological chemistry 34 29986887
2023 MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Molecular cancer research : MCR 32 36445328
2015 The avian-origin PB1 gene segment facilitated replication and transmissibility of the H3N2/1968 pandemic influenza virus. Journal of virology 31 25631088
2012 IL-10 transcription is negatively regulated by BAF180, a component of the SWI/SNF chromatin remodeling enzyme. BMC immunology 31 22336179
2014 Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Human pathology 30 25200863
2013 The influenza virus protein PB1-F2 interacts with IKKβ and modulates NF-κB signalling. PloS one 30 23704945
2020 Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis. Journal of medicinal chemistry 29 33216538
2018 PB1 and UBA domains of p62 are essential for aggresome-like induced structure formation. Biochemical and biophysical research communications 29 29966650
2019 Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay. ACS chemical biology 28 31714745
2017 PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology 28 28394406
2019 PBRM1 Regulates Stress Response in Epithelial Cells. iScience 27 31077944
2017 Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis 27 28092369
2019 High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1. Molecular oncology 25 30585695
2012 Cancer and the bromodomains of BAF180. Biochemical Society transactions 25 22435813
2024 The PB1 and the ZZ domain of the autophagy receptor p62/SQSTM1 regulate the interaction of p62/SQSTM1 with the autophagosome protein LC3B. Protein science : a publication of the Protein Society 24 37984441
2021 The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. European urology 24 34627641
2020 Influenza A virus PB1-F2 protein: An ambivalent innate immune modulator and virulence factor. Journal of leukocyte biology 24 32323899
2015 Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget 24 26452128
2022 PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner. Cancer immunology research 23 35013001
2021 Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Annals of translational medicine 23 33850862
2017 BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC urology 22 28327121
2015 Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology 22 25496315
2004 Influenza A virus PB1-F2 gene in recent Taiwanese isolates. Emerging infectious diseases 22 15200852
2017 BAF180: Its Roles in DNA Repair and Consequences in Cancer. ACS chemical biology 21 28921948
2020 A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells. Cell cycle (Georgetown, Tex.) 20 32093567
2023 PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma. Nature cell biology 19 37095322
2021 PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. Cell reports 19 34551289
2023 PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Frontiers in genetics 18 36699446
2015 PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest. Oncotarget 18 25978027
2013 PB1-F2 expedition from the whole protein through the domain to aa residue function. Acta virologica 18 23600872
2005 Crystal structure of the PB1 domain of NBR1. FEBS letters 18 16376336
2022 PBRM1 deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells. Journal of cellular and molecular medicine 17 35672925
2022 Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. Journal of medicinal chemistry 17 36227159
2021 PBRM1 Cooperates with YTHDF2 to Control HIF-1α Protein Translation. Cells 17 34200988
2021 Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma. Frontiers in oncology 17 34447697
2020 Determinants of PB1 Domain Interactions in Auxin Response Factor ARF5 and Repressor IAA17. Journal of molecular biology 17 32305460
2023 PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ precision oncology 16 37400502
2020 Influenza PB1-F2 Inhibits Avian MAVS Signaling. Viruses 16 32272772
2017 PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway. PloS one 16 28846693
2015 The BAH domain of BAF180 is required for PCNA ubiquitination. Mutation research 16 26117423
2015 PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. The Journal of pathology 16 26178300
2022 Viral PB1-F2 and host IFN-γ guide ILC2 and T cell activity during influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America 15 35169077
2020 Deep Evolutionary History of the Phox and Bem1 (PB1) Domain Across Eukaryotes. Scientific reports 15 32123237
2023 PBRM1 bromodomains associate with RNA to facilitate chromatin association. Nucleic acids research 14 36808431
2022 The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors. Cell death & disease 14 35368029
2020 PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. Science advances 14 33246952

Missed literature

Know a paper Affinage missed for PBRM1? Flag it for the maintainers and the community.

No submissions yet.